Document Detail


Pharmacotherapy of dilated cardiomyopathy.
MedLine Citation:
PMID:  25483945     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The pharmacological treatment of dilated cardiomyopathy overlaps with the treatment of heart failure. The primary objective of this treatment is to slow the progression of disease and improve quality and length of life. All patients, including those with asymptomatic dysfunction of the left ventricle, ought to receive angiotensin converting enzyme inhibitors, (in the case of intolerance, angiotensin receptor blockers), and beta blockers. The results of studies involving aliskiren have been, so far, disappointing. In symptomatic heart failure NYHA II-IV diuretics and mineralcorticoid receptor antagonists should be added to treatment. Digoxin is recommended in the event of atrial fibrillation, and otherwise only in the event of NYHA III and IV. Ivabradine is recommended for patients with sinus rhythm and pulse rate of > 70/min. In decompensation of heart failure, dobutamine, phosphodiesterase inhibitors or levosimendan are administered over the short-term. Of the recent treatment options, the vasopressin blocker and adenosine A1 receptor antagonist (rolofylline) were disappointing. One treatment with potential for the future is omecamtiv mecarbil, a heart myosin activator.
Authors:
Lenka Spinarova; Jindrich Spinar
Related Documents :
25332785 - Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillati...
782705 - 'wavy' myocardial fibers in spontaneous and experimental adrenergic cardiopathies.
21821525 - Remote ischemic preconditioning: current knowledge, unresolved questions, and future pr...
25350985 - Ivabradine improves left ventricular function during chronic hypertension in conscious ...
6545735 - Subcostal 2d echocardiography in cardiac pacing and intracardiac electrophysiologic stu...
16825135 - Effects of hydroxyethyl starch on cardiac output in hypotensive neonates: a comparison ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  21     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2014  
Date Detail:
Created Date:  2014-12-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  449-58     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeting cardiomyocyte Ca2+ homeostasis in heart failure.
Next Document:  New therapeutic aspects of inflammatory cardiomyopathy.